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Abstract : Matrix metalloproteinases (MMPs) is a family of collagenolytic enzymes 
and are associated with many pathological conditions. Especially, MMPs have a strong 
relation with tumor progression and invasion. In this review, we focused on 
association of MMPs and pancreatic diseases, and a potential treatment of MMPs 
inhibitors for pancreatic cancer. 
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Introduction 
Matrix metalloproteinases (MMPs) are a 
family of proteases that  degrade the collagen 
and are associated with many pathological 
conditions including pancreatic diseases . 
Recent investigations have revealed the 
MMPs are associated with the pathogenesis 
of cancer and inflammation. MMP activity 
is regulated a t  multiple steps". The MMP 
genes are transciptionally responsive t o  a 
number of biologically active agents, such as 
growth factors, hormones and oncogenes2'. 
MMP proteins are secreted as  inactive 
zymogens that require proteolytic processing 
t o  release the active enzyme. Another mecha- 
nism of control is blocking enzyme activity 
by physiologic MMP inhibitors; the circulat- 
ing alpha2-macroglobulin or the tissue inhibi- 
tors of metalloproteinases (TIMPs). The 
MMP-inhibitor complex is inactive and un- 
able t o  bind substrate3'. We have attempted 
t o  investigate MMPs in pancreatic juice of 
patients with chronic pancreatitis and pancre- 
atic cancer in order t o  diagnose them a t  early 
stage. In addition, MMPs is supposed t o  be ,a 
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new target for anti-cancer therapy. This 
review is focused on MMPs in pancreatic 
diseases, and treatment of MMP inhibitors 
for pancreatic cancer. 
Pancreatic cancer and MMPs 
Overexpression of several MMPs4 in 
pancreatic cancer tissues and cancer cell lines 
has been reported as well a s  other malig- 
nanciesg'. MMPs are thought t o  play a major 
role in metastasis by degradation of physio- 
logical barriers, promoting invation and 
entry into and out of blood lymphatic vessels 
in pancreatic cancer1''. MMP activity has been 
correlated with malignant potential in a 
number of studies~'".  
MMP-1 is thought to  be an interstitial 
collagenase, which degrades interstitial colla- 
gen. Ito et al.4)reported that  positive stain- 
ing for MMP-1 protein observed in cancer 
cells and stromal fibroblasts in pancreatic 
cancer compared with normal pancreas. They 
also demonstrated that patients with MMP-1 
positivity in the primary site had a signifi- 
cantly poorer prognosis than patients who 
were MMP-1 negative. These findings suggest 
that MMP-1 expression is related to  the 
carcinogenesis and prognosis of human pan- 
creatic ductal adenocarcinoma. On the other 
hand, Bramhall et aL6' reported that  MMP-1 
might not play an important role compared 
with MMP-2 in pancreatic cancer. Imbalance 
MMP-2 is known to  be a type IV 
collagenase, and plays a crucial role in the 
invasion of tumor cells because i t  degrades 
type IV collagen, which is one of the major 
components of the basement membranes1". 
Overexpression of MMP-2 mRNA was ob- 
served in stromal and tumor cells in pancre- 
atic cancer5'. Recently, it was found that 
epithelial cell membrane-bound MMPs, mem- 
brane-type MMPs (MT-MMPs) (designated 
MT1-MMP to  MT5-MMP), play crucial roles 
in the activation of MMP-2. MT-MMPs con- 
tain additional transmembrane domain, re- 
sulting in cell-surface localizationg' . MT1- 
MMP is involved in activation of proMMP-2 
by forming a complex with TIMP-2 on the 
cell surface, which serves as  a receptor for 
proMMP-2. An unbound MT1-MMP adjacent 
t o  this complex may initiate a second step 
leading t o  the activation of proMMP-2 l3 I". 
(Figure-1) Recent studies have shown that 
MT1-MMP itself can degrade the extra- 
cellular matrix '" 16). 
of MMP-1 to  TIMP-1 is also important 
Fig.1. Activation of MMP-2 
because TIMP-1 inactivated activated MMPs. 
Increased level of mRNA of TIMP-1 was also 
reported in pancreatic cancer5 6'. Since many 
cytokines and growth factors are known to  
affect expression of MMP-1 a t  the trans- 
criptional level. Comprehensive studies on 
MMP-1 and pancreatic cancer are needed. 
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Overexpression of MT1-MMP mRNA was 
observed in pancreatic cancer7) and MT1- 
MMP is exclusively located t o  the tumor 
epithelial  cell^^.^'. A good correlation was 
found between MT1-MMP and both MMP-2 
expression and activity in pancreatic cancer7). 
MMP-2 and MT1-MMP were also overe- 
xpressed in hamsters initiated with N- 
nitrosobis(2-oxopropyl)amine (BOP) which is 
a rapid-production model for pancreatic duct 
carcinomaln . Koshiba et  al. reported that  
activation ratio of MMP-2 was significantly 
higher in pancreatic cancer than in chronic 
pancreatitis and normal pancreas, although 
latent form of MMP-2 was detected in all 
samples of pancreatic carcinoma, chronic 
pancreatitis, and normal pancreatic tissue. 
Brook et  al.'" proposed another mechanism 
of localizing MMP-2 on the cell surface, 
demonstrating that  active MMP-2 binds 
directly to  integrin a v 3. MT1-MMP was 
suggested to  be involved activation of 
integrin-bound MMP-2"). 
Overexpression of MMP-2 was known to  be 
a poor prognostic marker in pancreatic can- 
cer. The MMP-2 activation ratio in pT3 
tumors was significantly higher than that  in 
pT1 tumors and also was significantly higher 
in pancreatic carcinoma specimens with 
histologically positive regional lymph node 
metastasis and distant metastasis than those 
without metastasiss). The ratio of type IV 
collagenase expression (mean of the expres- 
sion of MMP-2 and MMP-9) to  E-cadherin 
expression (MMP : E-cadherin ratio) a t  the 
periphery of the tumors was significantly 
higher in patients with recurrent disease than 
in patients who were disease free2". 
MMP-7 is known t o  be expressed in more 
than 75 per cent of gastric and colonic carci- 
n o m a ~ ~ ~ . ~ " .  According t o  Bramhall e t  al.'s 
report6', MMP-7 was expressed in 88 per cent 
of pancreatic carcinoma, suggesting that  it 
may have a role in its invasive phenotype. 
MMP-7 mRNA was localized to  the tumor 
epithelium, a s  well as  gastric and colonic 
carcinoma2I'. However, the findings of MMP-7 
mRNA expression in normal pancreatic 
t i s s ~ e s " ~ )  indicates tha t  i t  may also have 
physiological role in the pancreas. 
There is  little evidence supporting expres- 
sion of stromelysines (MMP-3, MMP-10, and 
MMP-11) in adenocarcinoma, although in 
squamous cell carcinoma stromelysin expres- 
sion was showed to  correlate with tumor 
progressionw. Gress e t  al.n) also failed t o  
detect MMP-3 expression in pancreatic can- 
cer. 
Several  investigator^^.^^' reported increased 
level of mRNA of MMP-9 in pancreatic 
cancer. Overexpression of type I1 TGF- j3 
receptors was observed in pancreatic cancer, 
and there was a strong correlation between 
the expression of type I1 TGF- j3 receptors 
and MMP-gn'. On the other hand, Koshiba et  
al.'I." demonstrated tha t  activated MMP-9 
was detected in normal pancreatic tissues as  
well as  pancreatic cancer and they concluded 
that  expression of activated MMP-9 was 
unrelated to  pancreatic cancer. In breast 
cancer, activated MMP-3 is a potent activa- 
tor  of proMMP-9, yielding activated MMPZ9). 
Furthermore, multiple transcriptional factors 
including NF K Bm) , SP-131) and AP-13", were 
known t o  be associated with regulating 
transcriptional activation of MMP-9. Taken 
together, further studies are needed t o  eluci- 
date the precise mechanism of MMP-9 in 
pancreatic cancer. 
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Therapeutic application of MMP 
inhibitors for pancreatic cancer 
As described above, overexpression of 
MMPs is associated with tumor spread and 
metastasis. Consequently, inhibitors of MMPs 
represent an attractive target for a new class 
of anticancer agents. Therefore, several 
MMP inhibitors have been developed and 
preclinical trials have confirmed a reduction 
in tumor spread and metastases3'). Marimastat  
is  the first  orally available MMP inhibitor 
(MMPI)  t o  be tested in humans and has 
been shown to  inhibit the spread and growth 
of pancreatic cancer in animal modelsa). 
Phase I1 studies which have used marimastat 
alone o r  in combination with other cytotoxic 
agents, have produced encouraging results 
with improved survival34). Phase I11 trials are 
now underway for the use of marimastat in 
advanced pancreatic cancer and as an 
adjuvant therapy in patients following resec- 
tion of pancreatic cancer3). 
Chronic pancreatitis and MMPs 
Theoretically, absolute or relative decrease 
of MMP considered t o  be reasonable because 
chronic pancreatitis is characteristic of pan- 
creatic fibrosis. However, the relationship 
between MMPs and TIMPs, and chronic 
pancreatitis is controversial. Ishihara et  al.%) 
reported tha t  positive immunostainings for 
MMP-2, MMP-9, TIMP-1, and TIMF-2 in 
ductal epithelia were 15 (75%), five (25% ) , 
four (20%), and 10 (50%) of patients with 
chronic pancreatitis, respectively, whereas no 
immunostaining was seen in normal pancreas. 
However, Gress et  al.25) reported tha t  tran- 
scripts for MMP-1, MMP-3 and TIMP-1 were 
not detectable in chronic pancreatitis and 
control tissues. 
Recent studies for pancreatic fibrosis 
have focused on the pancreatic stellate cell 
(PSC)s-39', which are morphologically similar 
to  the hepatic stellate cells t h a t  play a cen- 
tral role in liver fibrogenesis". Pancreatic 
stellate cells are activated on exposure t o  
ethanols), which is the major etiological 
factor in chronic pancreatitis. In liver fibro- 
sis, hepatic stellate cells are reported t o  
product MMPs and TIMPs such a s  MMP-141), 
MMP-2@, MMP-343), and TIMP-14'. Further- 
more, MMP-1 mRNA was detected in a t  
early stage, but TIMP-1 mRNA was 
up-regulated and MMP-1 mRNA became 
undetectable with activated hepatic stellate 
cells4". Further dynamic studies are needed t o  
be done in pancreatic fibrosis, because treat- 
ments of MMP inhibitor for benign diseases 
such a s  g lomer~lonephr i t i s~~) ,  brochial asth- 
ma@, and brain stroke47), have attempt t o  be 
applied. 
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マトリックスメタロブロテアーゼ（MMP）は，  
コラーゲン分解能を有し，種々の疾患との関連性  
が示唆されている。とりわけ∴癌の浸潤，転移に  
は密接な関係があるとされている。また，MMP  
l阻害剤を癌の治療に用いる試みもなされている。  
本稿ではMMPと膵疾患の関連性，MMP阻富剤  
の膵癌への応用の可能性について総説する。  
検索用語：MMP，TIMP，膵癌，慢性膵炎   
